| Literature DB >> 10419852 |
R M Eglen1, A Choppin, M P Dillon, S Hegde.
Abstract
Over the past year, the introduction of novel ligands has accelerated the classification of muscarinic receptor subtypes and has led to a better understanding of their physiological role. Important in this respect is the recent recognition of the exquisite selectivity of a series of snake toxins, enabling better definition of the muscarinic subtype 4 receptor. Moreover, several compounds, both agonists and antagonists, are progressing in advanced clinical trials for the treatment of several conditions, including Alzheimer's disease, pain, urinary incontinence and chronic obstructive pulmonary disease.Entities:
Mesh：
Substances：
Year: 1999 PMID： 10419852 DOI： 10.1016/S1367-5931(99)80063-5
Source DB: PubMed Journal: Curr Opin Chem Biol ISSN： 1367-5931 Impact factor: 8.822